Showing 1 - 10 of 332
We consider four models of consumption that differ with respect to efficient risk-sharing and altruism. They range from complete markets with altruism to family risk-sharing. We use a matched sample of parents and independent children available from the Panel Study of Income Dynamics to...
Persistent link: https://www.econbiz.de/10012475159
This paper considers a market in which only the incumbent's quality is publicly known. The entrant's quality is observed by the incumbent and some fraction of informed consumers. This leads to price signalling rivalry between the duopolists, because the incumbent gains and the entrant loses when...
Persistent link: https://www.econbiz.de/10009404774
This paper studies the cross-country patterns of risky innovation and growth through the lens of international trade. We use a simple theoretical framework of risky quality upgrading by firms under varying levels of financial development to derive two predictions. First, the mean rate of quality...
Persistent link: https://www.econbiz.de/10014226112
Persistent link: https://www.econbiz.de/10003532077
In what follows we provide a conceptually correct procedure for determining whether a risky project passes the "potential Pareto improvement" welfare criterion which forms the normative basis of cost-benefit analysis. In this approach the role of secondary markets in providing opportunities for...
Persistent link: https://www.econbiz.de/10012478938
Persistent link: https://www.econbiz.de/10012495049
Persistent link: https://www.econbiz.de/10012264759
We study economies in which agents face Knightian uncertainty about state prices. Knightian uncertainty leads naturally to nonlinear expectations. We introduce a corresponding equilibrium concept with sublinear prices and prove that equilibria exist under weak conditions. In general, such...
Persistent link: https://www.econbiz.de/10011975297
Persistent link: https://www.econbiz.de/10013433692
Between 1810 and 1939, real per capita spending on patent medicines grew by a factor of 114; real per capita GDP by a factor of 5. The long-term growth and survival this industry is puzzling when juxtaposed with standard historical accounts, which typically portray patent medicines as quack...
Persistent link: https://www.econbiz.de/10012462953